Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus
Yukihiro Kitanaga(Astellas Pharma (Japan)), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Fumitaka Kinugasa(Astellas Pharma (Japan)), Daisuke Yamajuku(Astellas Pharma (Japan)), Yuya Kondo(University of Tsukuba), Hiroko Yoshinari(University of Occupational and Environmental Health Japan), Tatsuaki Morokata(Astellas Pharma (Japan)), Mutsumi Seki(Astellas Pharma (Japan)), Shingo Nakayamada(University of Occupational and Environmental Health Japan), Koji Nakamura(Tohoku University), Takayuki Sumida(University of Tsukuba), Yoko Kaneko(Keio University), Satoshi Kubo(Forestry and Forest Products Research Institute), Masashi Maeda(Astellas Pharma (Japan))
Cited by 3
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Inhibition of cellulase, xylanase and β-glucosidase activities by softwood lignin preparations
|Journal of Biotechnology|2006|622
Hydrogen Bonding in Lignin: A Fourier Transform Infrared Model Compound Study
|Biomacromolecules|2005|513
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|413